
Ole Ahlehoff

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10547368/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ: British Medical Journal, 2011, 342, d124-d124.	2.3	1,143
2	Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a â€real world' nationwide cohort study. Thrombosis and Haemostasis, 2011, 106, 739-749.	3.4	393
3	The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Annals of the Rheumatic Diseases, 2011, 70, 929-934.	0.9	338
4	Proton-Pump Inhibitors Are Associated With Increased Cardiovascular Risk Independent of Clopidogrel Use. Annals of Internal Medicine, 2010, 153, 378.	3.9	233
5	Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. European Heart Journal, 2012, 33, 2054-2064.	2.2	196
6	Disease Activity in Inflammatory Bowel Disease Is Associated with Increased Risk of Myocardial Infarction, Stroke and Cardiovascular Death – A Danish Nationwide Cohort Study. PLoS ONE, 2013, 8, e56944.	2.5	182
7	Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ: British Medical Journal, 2011, 342, d2690-d2690.	2.3	161
8	Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study. BMJ: British Medical Journal, 2012, 344, e1257-e1257.	2.3	147
9	Increased risk of atrial fibrillation and stroke during active stages of inflammatory bowel disease: a nationwide study. Europace, 2014, 16, 477-484.	1.7	107
10	Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Annals of the Rheumatic Diseases, 2014, 73, 1515-1521.	0.9	89
11	Psoriasis Carries an Increased Risk of Venous Thromboembolism: A Danish Nationwide Cohort Study. PLoS ONE, 2011, 6, e18125.	2.5	83
12	Psoriasis and risk of heart failure: a nationwide cohort study. European Journal of Heart Failure, 2014, 16, 743-748.	7.1	75
13	Psoriasis and New-Onset Diabetes. Diabetes Care, 2013, 36, 2402-2407.	8.6	65
14	Inflammatory Bowel Disease Is Associated With an Increased Risk of Hospitalization for Heart Failure. Circulation: Heart Failure, 2014, 7, 717-722.	3.9	63
15	Randomized Comparison of the Polymer-Free Biolimus-Coated BioFreedom Stent With the Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Orsiro Stent in an All-Comers Population Treated With Percutaneous Coronary Intervention. Circulation, 2020, 141, 2052-2063.	1.6	48
16	Pharmacological Undertreatment of Coronary Risk Factors in Patients with Psoriasis: Observational Study of the Danish Nationwide Registries. PLoS ONE, 2012, 7, e36342.	2.5	48
17	Psoriasis and cardiovascular events: updating the evidence. Archives of Dermatological Research, 2017, 309, 225-228.	1.9	47
18	Incident Heart Failure in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study. Journal of the American Heart Association, 2018, 7, .	3.7	40

OLE AHLEHOFF

#	Article	IF	CITATIONS
19	Initiation and adherence to secondary prevention pharmacotherapy after myocardial infarction in patients with rheumatoid arthritis: a nationwide cohort study. Annals of the Rheumatic Diseases, 2012, 71, 1496-1501.	0.9	38
20	Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis. Journal of the American Academy of Dermatology, 2016, 75, 897-905.	1.2	38
21	Hormone Replacement Therapy and Risk of New-Onset Atrial Fibrillation after Myocardial Infarction - A Nationwide Cohort Study. PLoS ONE, 2012, 7, e51580.	2.5	27
22	Randomized Clinical Comparison of the Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Combo Stent With the Sirolimus-Eluting Orsiro Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT X Trial. Circulation, 2021, 143, 2155-2165.	1.6	25
23	Nationwide Study on the Risk of Abdominal Aortic Aneurysms in Patients With Psoriasis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1043-1048.	2.4	20
24	Prognosis After First-Time Myocardial Infarction in Patients With Inflammatory Bowel Disease According to Disease Activity. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 857-862.	2.2	18
25	Increased risk of aortic valve stenosis in patients with psoriasis: a nationwide cohort study. European Heart Journal, 2015, 36, 2177-2183.	2.2	18
26	Management of Cardiovascular Risk in Patients with Chronic Inflammatory Diseases: Current Evidence and Future Perspectives. American Journal of Cardiovascular Drugs, 2016, 16, 1-8.	2.2	18
27	Localized Scleroderma, Systemic Sclerosis and Cardiovascular Risk: A Danish Nationwide Cohort Study. Acta Dermato-Venereologica, 2018, 98, 361-365.	1.3	14
28	SuPAR is associated with death and adverse cardiovascular outcomes in patients with suspected coronary artery disease. Scandinavian Cardiovascular Journal, 2020, 54, 339-345.	1.2	11
29	Time Trends in Simple Congenital Heart Disease Over 39 Years: A Danish Nationwide Study. Journal of the American Heart Association, 2021, 10, e020375.	3.7	11
30	Prognosis after percutaneous coronary intervention in patients with psoriasis: a cohort study using Danish nationwide registries. BMC Cardiovascular Disorders, 2012, 12, 79.	1.7	9
31	Cardiovascular aspects of psoriasis: an updated review. International Journal of Dermatology, 2014, 53, e337.	1.0	5
32	Psoriasis and Cardiovascular Disease: epidemiological studies. Danish Medical Bulletin, 2011, 58, B4347.	0.3	5
33	Optical Coherence Tomography- Versus Angiography-Guided Magnesium Bioresorbable Scaffold Implantation in NSTEMI Patients. Cardiovascular Revascularization Medicine, 2022, 40, 101-110.	0.8	2
34	Influence of Plaque Characteristics on Early Vascular Healing in Patients With ST-Elevation Myocardial Infarction. Cardiovascular Revascularization Medicine, 2021, 30, 50-58.	0.8	1
35	Effect of implantable cardioverterâ€defibrillators in patients with nonâ€ischaemic systolic heart failure and concurrent coronary atherosclerosis. ESC Heart Failure, 2022, 9, 1287-1293.	3.1	1
36	Culprit lesion morphology in patients with ST-segment elevation myocardial infarction assessed by optical coherence tomography. Coronary Artery Disease, 2020, 31, 671-677.	0.7	0

#	Article	IF	CITATIONS
37	Early vascular healing after implantation of the polymer-free biolimus-eluting stent or the ultrathin strut biodegradable polymer sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction. Coronary Artery Disease, 2022, Publish Ahead of Print, .	0.7	0